1. |
Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. 2001.
|
2. |
Kimby E, Brandt L, Nygren P. A systematic overview of chemotherapy effects in aggressive non-Hodgkin’s lymphoma[J]. Acta Oncol, 2001; 40(2-3): 198-212.
|
3. |
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma[J]. N Engl J Med, 1993; 328(14): 1 002-1 006.
|
4. |
Tilly H, Lepage E, Coiffier B. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin’s lymphoma: the LNH93-5 study[J]. Blood, 2000; 96: 832a. abstract.
|
5. |
Kouroukis CT, Browman GP, Esmail R, Meyer RM. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review[J]. Ann Intern Med, 2002; 15; 136(2): 144-152.
|
6. |
No authors listed.Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed[J].Prescrire Int, 2003; 12(66): 125-126.
|
7. |
W(o")hrer SR. Cyclophosphamide,doxorubicin,vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large-B-cell lymphoma[J]. Ann Oncol, 2004;15(7): 1 086-1 090.
|
8. |
Portlock CS. Rituximab and CHOP for elderly patients with diffuse large-B-cell lymphoma[J]. Curr Oncol Rep, 2003; 5(5): 357.
|
9. |
Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkins lymphoma[J]. Br J Haematol, 2003; 121(1): 44-48.
|
10. |
Kimby E, Brandt L, Nygren P, Glimelius B; SBU-group.A systematic overview of chemotherapy effects in aggressive non-Hodgkins lymphoma[J]. Acta Oncol, 2001; 40(2-3): 198-212.
|
11. |
Coiffier B.Immunochemotherapy: the new standard in aggressive non-Hodgkins lymphoma in the elderly[J]. Semin Oncol, 2003; 30(1 Suppl 2): 21-27.
|
12. |
Coiffier B, Lepage E, Briere J.CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma[J]. N Engl J Med, 2002; 346(4): 235-242.
|
13. |
Hannaford P. Rituximab plus CHOP for diffuse large-B-Cell lymphoma[J]. N Engl J Med, 2002; 346(23): 1 830-1 831.
|
14. |
The International Non-Hodgkins Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkins lymphoma[J]. N Engl J Med, 1993; 329(14): 987-994.
|
15. |
Cancer Therapy Evaluation Program. Common toxicity criteria[M], version2.0. Bethesda, Md.: National Cancer Institute, March 1998.
|
16. |
Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkins lymphoma: systematic review and economic evaluation[J]. Health Technol Assess, 2004; 8(37): iii, ix-xi,1-82.
|
17. |
Heson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J]. J Clin Oncol, 1999; 17: 1 244. [Erratum,] J Clin Oncol 2000; 18: 2 351.
|